Maximus, Inc.

Maximus has raised its fiscal 2026 adjusted EPS guidance to $8.25–$8.55, driven by AI-driven automation and operational improvements. The company also beat Q2 FY2026 EPS expectations ($2.07 vs. $2.02 forecast), and its Zacks rating was upgraded to Strong Buy following a 6.7% upward revision in consensus estimates over three months.

Despite EPS beats, Maximus reported a notable revenue shortfall in Q2 FY2026 ($1.31B vs. $1.37B forecast). Zacks notes the FY2025 EPS consensus of $6.49 is unchanged year-over-year, suggesting stabilization rather than genuine growth — and a projected 20% year-over-year EPS decline for the next quarter.

Maximus trades near its 52-week low and appears significantly undervalued according to InvestingPro's Fair Value analysis, with Morningstar noting the stock trades 21% below fair value despite a 33% dividend increase. The company's price-to-sales ratio of 0.6x is modest relative to peers, suggesting an attractive entry point.

The stock is down 33% year-to-date and trades well below all major moving averages — the MA-50 at $60.88 and the MA-200 at $76.86 — with technical indicators broadly signaling 'Sell' or 'Neutral'. Analysts on Seeking Alpha have also labeled the stock 'Overvalued' and noted fading healthcare growth as a structural headwind.

Maximus is described as a market leader in non-cyclical government services with a stronger federal focus, targeting $5.2B–$5.35B in FY2025 revenue. Its 22-year consecutive dividend payment track record and steady contract base reflect resilient demand for outsourced government health and business process services.

Maximus posted a meaningful revenue miss in Q2 FY2026, generating $1.31B against a $1.37B forecast, raising concerns about contract volume and scope. Seeking Alpha analysis flags that 'healthcare growth fades' and that 'growth may be uneven,' questioning whether federal spending dynamics can sustain current revenue projections.